Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid

作者: Sachin R. Shah , Gary W. Jean , Sidney V. Keisner , Sarah M. Gressett Ussery , Jonathan E. Dowell

DOI: 10.1007/S00520-010-1067-7

关键词: Multiple myelomaRetrospective cohort studyBone metastasisUrologyCreatinineRenal functionSurgeryCancerMedicineAcute kidney injuryZoledronic acid

摘要: Purpose The purpose of this study was to evaluate the incidence acute renal failure (ARF) in patients with mild moderate dysfunction, receiving renally adjusted zoledronic acid (ZA) and compare it normal baseline function, standard-dose ZA.

参考文章(16)
Gary R Hudes, Corey J Langer, Dwight D Kloth, Raymond S McDermott, Hao Wang, Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. The journal of supportive oncology. ,vol. 4, pp. 524- 529 ,(2006)
Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580
William K. Oh, Kevin Proctor, Mari Nakabayashi, Carolyn Evan, Lauren K. Tormey, Timothy Daskivich, Lucia Antràs, Michael Smith, Maureen P. Neary, Mei Sheng Duh, The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid Cancer. ,vol. 109, pp. 1090- 1096 ,(2007) , 10.1002/CNCR.22504
Ingo J. Diel, Rudolf Weide, Hubert Köppler, Lucia Antràs, Michael Smith, Jesse Green, Neil Wintfeld, Maureen Neary, Mei Sheng Duh, Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review Supportive Care in Cancer. ,vol. 17, pp. 719- 725 ,(2009) , 10.1007/S00520-008-0553-7
Glen S. Markowitz, Paul L. Fine, Jay I. Stack, Cheryl L. Kunis, Jai Radhakrishnan, Winicjusz Palecki, Jin Park, Samih H. Nasr, Shirley Hoh, David S. Siegel, Vivette D. D'Agati, Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney International. ,vol. 64, pp. 281- 289 ,(2003) , 10.1046/J.1523-1755.2003.00071.X
Lee S. Rosen, David Gordon, Mary Kaminski, Anthony Howell, Andrew Belch, John Mackey, Justus Apffelstaedt, Mohamad A. Hussein, Robert E. Coleman, Dirk J. Reitsma, Bee-Lian Chen, John J. Seaman, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. ,vol. 98, pp. 1735- 1744 ,(2003) , 10.1002/CNCR.11701
Allan Lipton, Richard J. Cook, Pierre Major, Matthew R. Smith, Robert E. Coleman, Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Oncologist. ,vol. 12, pp. 1035- 1043 ,(2007) , 10.1634/THEONCOLOGIST.12-9-1035
Lee S. Rosen, David Gordon, Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh, M. Krzakowski, M. Pawlicki, Paul de Souza, Ming Zheng, Gladys Urbanowitz, Dirk Reitsma, John J. Seaman, Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology. ,vol. 21, pp. 3150- 3157 ,(2003) , 10.1200/JCO.2003.04.105
J. Apffelstaedt, Dirk J. Reitsma, Anthony Howell, John Mackey, John J. Seaman, Lee S. Rosen, Robert E. Coleman, Yvonne Ambros, Bee Lian Chen, David Gordon, Mohamed Hussein, Mary Kaminski, Andrew Belch, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer Journal. ,vol. 7, pp. 377- 387 ,(2001)